Overcoming challenges of amyloidosis management with earlier diagnosis and novel treatments
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released:
7 January 2022
Valid for credit through:
7 March 2022
CME accredited by:
Hong Kong College of Community Medicine - 0.5
The Hong Kong College of Pathologists - 1
Hong Kong College of Physicians - 1
About the programme
Amyloid light chain (AL) amyloidosis requires early diagnosis for better clinical outcomes.1 However, this disease can be difficult to diagnose because of its rarity and subtle symptoms, with 50% of patients presenting with stage 3 disease at initial diagnosis. Differentiation of AL amyloidosis from other subtypes of amyloidosis such as wild-type transthyretin (ATTR) amyloidosis is also critical for deciding appropriate therapy.1 In recent years, there has been major advancement in anti-plasma cell treatments.1 For example, addition of subcutaneous daratumumab (DARA) to the standard of care combination of bortezomib, cyclophosphamide, and dexamethasone (VCd) was shown to significantly increase hematologic complete response rates among AL amyloidosis patients.2
In this video, Professor Ashutosh Wechalekar of University College London shared the latest diagnostic approach for early identification of AL amyloidosis and the recent advancement in anti-plasma cell treatments for improving clinical outcomes among AL amyloidosis patients.
- Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019;34(9):1460-1466.
- Kastritis E et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. NEJM. 2021;385:46-58.
Professor Ashutosh Wechalekar
Senior lecturer
Honorary consultant haematologist
University College London,
Royal Free London NHS Foundation Trust,
Lodon, UK
Disclaimer
This is an educational programme developed through unrestricted support from the medical community, for the purpose of continuing medical education only. The views expressed on this portal reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.